Literature DB >> 15701965

p53--a key player in tumoral and evolutionary adaptation: a lesson from the Israeli blind subterranean mole rat.

Aaron Avivi1, Osnat Ashur-Fabian, Ninette Amariglio, Eviatar Nevo, Gideon Rechavi.   

Abstract

p53 is a transcription factor involved in maintaining genomic integrity by regulating genes involved in cell cycle arrest, DNA repair, and programmed cell death. Various post transcriptional modifications result in activated p53 with varying binding affinity to its targets. The other members of the p53 family (p63, p73) and associated proteins also contribute to the specificity of gene activation resulting in the final cell responses. p53 is commonly mutated in human cancer and is activated by diverse cellular events, including hypoxia. Many sources of genetic diversity, including random or stress-related mutagenesis, affect normal species evolution. The blind subterranean mole rat lives in sealed underground tunnels, subjected to routine hypoxia due to abrupt and sharp changes in O2 supply. We cloned the mole rat's p53 gene and identified two amino acid substitutions in its binding domain, in the same positions that are mutated in cancer. These substitutions lead to increased p53 activation of DNA-repair elements and reduced activation of apoptotic genes. We propose that sequence-specific changes in the mole rat's p53 gene provide an example of how transcription factors that regulate many genes can also account for rapid and broad phenotypic diversity by altering the binding affinity to individual target genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701965     DOI: 10.4161/cc.4.3.1534

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  Adaptive evolution of heparanase in hypoxia-tolerant Spalax: gene cloning and identification of a unique splice variant.

Authors:  Nicola J Nasser; Eviatar Nevo; Itay Shafat; Neta Ilan; Israel Vlodavsky; Aaron Avivi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-04       Impact factor: 11.205

Review 2.  Molecular signatures of longevity: Insights from cross-species comparative studies.

Authors:  Siming Ma; Vadim N Gladyshev
Journal:  Semin Cell Dev Biol       Date:  2017-08-08       Impact factor: 7.727

3.  Response to Different Oxygen Partial Pressures and Evolution Analysis of Apoptosis-Related Genes in Plateau Zokor (Myospalax baileyi).

Authors:  Zhifang An; Xiaoqi Chen; Jimei Li
Journal:  Front Genet       Date:  2022-06-08       Impact factor: 4.772

Review 4.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 5.  Cellular adaptation to hypoxia and p53 transcription regulation.

Authors:  Yang Zhao; Xue-qun Chen; Ji-zeng Du
Journal:  J Zhejiang Univ Sci B       Date:  2009-05       Impact factor: 3.066

Review 6.  Molecular Mechanisms Determining Lifespan in Short- and Long-Lived Species.

Authors:  Xiao Tian; Andrei Seluanov; Vera Gorbunova
Journal:  Trends Endocrinol Metab       Date:  2017-09-07       Impact factor: 12.015

7.  Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis.

Authors:  Nicola J Nasser; Aaron Avivi; Itay Shafat; Evgeny Edovitsky; Eyal Zcharia; Neta Ilan; Israel Vlodavsky; Eviatar Nevo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

8.  Evolution under environmental stress at macro- and microscales.

Authors:  Eviatar Nevo
Journal:  Genome Biol Evol       Date:  2011       Impact factor: 3.416

9.  Pronounced cancer resistance in a subterranean rodent, the blind mole-rat, Spalax: in vivo and in vitro evidence.

Authors:  Irena Manov; Mark Hirsh; Theodore C Iancu; Assaf Malik; Nick Sotnichenko; Mark Band; Aaron Avivi; Imad Shams
Journal:  BMC Biol       Date:  2013-08-09       Impact factor: 7.431

10.  Lipid profile and serum characteristics of the blind subterranean mole rat, Spalax.

Authors:  Nicola J Nasser; Marielle Kaplan; Eviatar Nevo; Michael Aviram
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.